Mycosis fungoides is the commonest type of cutaneous T-cell lymphoma. It is also called as Alibert-Bazin syndrome or granuloma fungoides. Mycosis Fungoides are an uncommon, heterogeneous group of non-Hodgkin lymphomas (NHLs) of T- and B-cell origin where the skin is the primary organ of involvement. Its clinical manifestation includes many clinical and histological forms; such as a patch, plaque, tumor nodules; erythrodermic and poikoilodermous stages which may differ with different stages. The very severe stage of Mycosis fungoides is extracutaneous where any organ may be involved. Only 20 cases of Bulla formation are reported in the literature so far, making it a very rare finding in mycosis fungoides. The majority of reported cases are in adult males. Case presentation: A 45-year-old male, a case of mycosis fungoides IIB, is described in this case report. He presented in an advanced stage of disease with multiple ulcers over the face, bilateral upper limbs, trunk, and back for 6 Months. Conclusion: mycosis fungoides is a very important clinical subtype of cutaneous T-cell lymphoma. Mycosis fungoides IIB represents a particularly aggressive form of mycosis fungoides. The progression of extracutaneous spread in our patient confirms the advanced stage of the disease. The patient was given topical glucocorticoids, which will show improvement. Still, further awareness of the disease among physicians and pathologists is needed.
| Published in | International Journal of Clinical and Experimental Medical Sciences (Volume 8, Issue 4) |
| DOI | 10.11648/j.ijcems.20220804.12 |
| Page(s) | 56-61 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Mycosis Fungoides, Tumor Stage, Skin Nodule, Cutaneous T-Cell Lymphoma
| [1] | Alibert JLM (1806) Description des Maladies de la peau observes a I Hospital Saint Louis, Paris, Borris 157. |
| [2] | Arafah M, Zaidi SN, Al Ghamdi K. The histological spectrum of early mycosis fungoides: a study of 58 Saudi Arab patients. Oman Med J. 2012; 27 (2): 134–9. |
| [3] | Ballanger F, Bressollette C, Volteau C, Planche L, Dreno B. Cytomegalovi- rus: its potential role in the development of cutaneous T-cell lymphoma. Exp Dermatol. 2009; 18 (6): 574–6. |
| [4] | Barcos M (1993) Mycosis fungoides, diagnosis and patho- genesis. Clin Pathol 99: 452–458. |
| [5] | Bertram F, Bröcker EB, Zillikens D, Schmidt E: Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009, 13: 379-387. |
| [6] | Bowman PH, Hogan DJ, Sanusi ID: Mycosis fungoides bullosa: report of a case and review of the literature. J Am Acad Dermatol 2001, 45: 934-939. |
| [7] | Burg G, Dummer R, Haeffner A. From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors. Arch Dermatol. 2001; 137: 949. |
| [8] | Courgnaud V, Duthanh A, Guillot B, Sitbon M, Dereure O. Absence of HTLV- related sequences in skin lesions and peripheral blood of cutaneous T-cell lym- phomas. J Invest Dermatol. 2009; 129 (10): 2520–2. |
| [9] | Dummer R, Dreyling M. Primary cutaneous lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol. 2008; 19 (suppl 2): 72–6. |
| [10] | Gantcheva M, Lalova A, Broshtilova V, Negenzova Z, Tsankov N: Vesicular mycosis fungoides. J Dtsch Dermatol Ges 2005, 3: 898-900. |
| [11] | Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004; 350 (19): 1978–88. |
| [12] | Glusac EJ (2003) Criterion by criterion, mycosis fungoides. Am J Dermatopathol 25: 264–269. |
| [13] | Ho KK, Browne A, Fitzgibbons J, Carney D, Powell FC: Mycosis fungoides bullosa simulating pyoderma gangrenosum. Br J Dermatol 2000, 142: 124-127. |
| [14] | Hortwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008; 6 (4): 436–42. |
| [15] | Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphy- lococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997; 89 (1): 32–40. |
| [16] | Kartsonis J, Brettschneider F, Weissmann A, Rosen L: Mycosis fungoides bullosa. Am J Dermatopathol 1990, 12: 76-80. |
| [17] | Kazakov DV, Burg G, Kempf W: Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol 2004, 18: 397-415. |
| [18] | Kim YH, Hoppe RT (1999) Mycosis fungoides and the Sezary syndrome. Semin Oncol 26: 276–289. |
| [19] | Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clin Dermatol. 2004; 22 (3): 197–208. |
| [20] | Konrad K: Mycosis fungoides bullosa. Lymphoproliferative Diseases of the Skin New York: Springer VerlagChristophers E, Goos M 1979, 157-162. |
| [21] | Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol. 1995; 13 (1): 257–63. |
| [22] | Latkowski JA, Heald PW. Cutaneous T-cell lymphomas. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI eds. Fitzpatrick’s Dermatology in General Medicine. Vol 2. 6th ed. New York: McGraw-Hill; 2003: 1537–58. |
| [23] | Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti- CD52 monoclonal antibody) in patients with advanced mycosis fungoides/ Sezary syndrome. Blood. 2003; 101 (11): 4267–72. |
| [24] | Lutzner M, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disor- ders. Ann Intern Med. 1975; 83: 534–52. |
| [25] | Morales-Suárez-Varela MM, Olsen J, Johansen P, et al. Occupational risk fac- tors for mycosis fungoides: a European multicenter case-control study. J Occup Environ Med. 2004; 46 (3): 205–11. |
| [26] | Murphy GF, Schwarting R (2005) Cutaneous lymphomas and leukemias. In Lever’s histopathology of the skin, 9th edition. Lippincot Williams and Wilkins 927–978. |
| [27] | Nagatani T, Matsuzaki T, Lemonto G, et al. (1990) Compara- tive study of cutaneous T-cell lymphoma and adult T-cell lymphoma/leukemia, clinical, histopathologic and immuno- histochemical analysis. Cancer 66: 2380–2386. |
| [28] | Naraghi ZS, Seirafi H, Valikhani M, Farnaghi F, KavusiDowlati Y. Assess- ment of histologic criteria in the diagnosis of mycosis fungoides. Int J Dermatol. 2003; 42: 45–52. |
| [29] | Novelli M, Merlino C, Ponti R, et al. Epstein–Barr virus in cutaneous T-cell lymphomas: evaluation of the viral presence and significance in skin and periph- eral blood. J Invest Dermatol. 2009; 129 (6): 1556–61. |
| [30] | Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and clas- sification of mycosis fungoides and Sezary syndrome: a proposal of the Interna- tional Society for Cutaneous Lymphomas (ISCL) and the cutaneous task force of the European Organization for Research and Treatment of Cancer (EORTC). Blood. 2007; 110 (6): 1713–22. |
| [31] | Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the interna- tional society for cutaneous lymphomas, the United Stated Cutaneous Lymphoma Consortium, and the cutaneous lymphoma task force of the European Organisa- tion for Research and Treatment of Cancer. J Clin Oncol. 2011; 29 (18): 2598–607. |
| [32] | Patterson J, Ali M, Murray J, Hatra T: Bullous pemphigoid: occurrence in patient with mycosis fungoides receiving PUVA and topical mustard therapy. Int J Dermatol 1985, 24: 173-176. |
| [33] | Pope E, Weitzman S, Ngan B, et al. Mycosis fungoides in the pediatric popula- tion: report from an international childhood registry of cutaneous lymphoma. J Cutan Med Surg. 2010; 14 (1): 1–6. |
| [34] | Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009; 114 (20): 4337–53. |
| [35] | Robert C, Kupper TS. Inflammatory skin diseases, T-cells, and immune surveil- lance. N Engl J Med. 1999; 341: 1817–28. |
| [36] | Smoller BR, Bishop K, Glusac E, Kim YH, Hedrickson M. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol. 1995; 19: 1423–30. |
| [37] | Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosis fungoides-a disease of antigen persistence. Br J Dermatol. 1974; 91 (6): 607–16. |
| [38] | Van Doorn R, Van Haselen CW, Voorst Vader PC, et al. (2000) Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 136: 504–510. |
| [39] | Vergier B, De Muret A, Beylot-Barry M, et al. (2000) Trans- formation of mycosis fungoides: Clinicopathological and prognostic features of 45 cases. French study group of cuta- neous lymphomas. Blood 95: 2212–2218. |
| [40] | Vidulich KA, Rady PL, He Q, Tyring SK, Duvic M. Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series. Int J Dermatol. 2009; 48 (6): 598–602. |
| [41] | Vonderheid EC, Bigler RD, Hou JS. On the possible relationship between staphylococcal superantigens and increased Vbeta 5.1 usage in cutaneous T-cell lymphoma. Br J Dermatol. 2005; 152 (4): 825–6. |
| [42] | Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to envi- ronmental exposures and immune response: a case-control study. J Natl Cancer Inst. 1989; 81: 1560–3. |
| [43] | Willemze R, Jaffe ES, Burg G, et al. WHO–EORTC classification for cutane- ous lymphomas. Blood. 2005; 105 (10): 3768–85. |
| [44] | Yoo EK, Cassin M, Lessin ST, Rook AH. Complete molecular remission dur- ing biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol. 2001; 45: 208. |
| [45] | Zackheim HS, Amin S, Kashani-Saket M, et al. (1999) Prognosis in cutaneous T-cell lymphoma by skin stage: Long term survival in 489 patients. J Am Acad Dermatol 40: 418–425. |
| [46] | Zendri E, Pilotti E, Perez M, et al. The HTLV tax-like sequences in cutaneous T-cell lymphoma patients. J Invest Dermatol. 2008; 128 (2): 489–92. |
APA Style
Ufaque Batool, Reema Samo, Rizwan Ali Lakho, Khushboo Jawed, Hassan Jawed. (2022). Mycosis Fungoides: A Clinical Case Report & Review. International Journal of Clinical and Experimental Medical Sciences, 8(4), 56-61. https://doi.org/10.11648/j.ijcems.20220804.12
ACS Style
Ufaque Batool; Reema Samo; Rizwan Ali Lakho; Khushboo Jawed; Hassan Jawed. Mycosis Fungoides: A Clinical Case Report & Review. Int. J. Clin. Exp. Med. Sci. 2022, 8(4), 56-61. doi: 10.11648/j.ijcems.20220804.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcems.20220804.12,
author = {Ufaque Batool and Reema Samo and Rizwan Ali Lakho and Khushboo Jawed and Hassan Jawed},
title = {Mycosis Fungoides: A Clinical Case Report & Review},
journal = {International Journal of Clinical and Experimental Medical Sciences},
volume = {8},
number = {4},
pages = {56-61},
doi = {10.11648/j.ijcems.20220804.12},
url = {https://doi.org/10.11648/j.ijcems.20220804.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20220804.12},
abstract = {Mycosis fungoides is the commonest type of cutaneous T-cell lymphoma. It is also called as Alibert-Bazin syndrome or granuloma fungoides. Mycosis Fungoides are an uncommon, heterogeneous group of non-Hodgkin lymphomas (NHLs) of T- and B-cell origin where the skin is the primary organ of involvement. Its clinical manifestation includes many clinical and histological forms; such as a patch, plaque, tumor nodules; erythrodermic and poikoilodermous stages which may differ with different stages. The very severe stage of Mycosis fungoides is extracutaneous where any organ may be involved. Only 20 cases of Bulla formation are reported in the literature so far, making it a very rare finding in mycosis fungoides. The majority of reported cases are in adult males. Case presentation: A 45-year-old male, a case of mycosis fungoides IIB, is described in this case report. He presented in an advanced stage of disease with multiple ulcers over the face, bilateral upper limbs, trunk, and back for 6 Months. Conclusion: mycosis fungoides is a very important clinical subtype of cutaneous T-cell lymphoma. Mycosis fungoides IIB represents a particularly aggressive form of mycosis fungoides. The progression of extracutaneous spread in our patient confirms the advanced stage of the disease. The patient was given topical glucocorticoids, which will show improvement. Still, further awareness of the disease among physicians and pathologists is needed.},
year = {2022}
}
TY - JOUR T1 - Mycosis Fungoides: A Clinical Case Report & Review AU - Ufaque Batool AU - Reema Samo AU - Rizwan Ali Lakho AU - Khushboo Jawed AU - Hassan Jawed Y1 - 2022/08/05 PY - 2022 N1 - https://doi.org/10.11648/j.ijcems.20220804.12 DO - 10.11648/j.ijcems.20220804.12 T2 - International Journal of Clinical and Experimental Medical Sciences JF - International Journal of Clinical and Experimental Medical Sciences JO - International Journal of Clinical and Experimental Medical Sciences SP - 56 EP - 61 PB - Science Publishing Group SN - 2469-8032 UR - https://doi.org/10.11648/j.ijcems.20220804.12 AB - Mycosis fungoides is the commonest type of cutaneous T-cell lymphoma. It is also called as Alibert-Bazin syndrome or granuloma fungoides. Mycosis Fungoides are an uncommon, heterogeneous group of non-Hodgkin lymphomas (NHLs) of T- and B-cell origin where the skin is the primary organ of involvement. Its clinical manifestation includes many clinical and histological forms; such as a patch, plaque, tumor nodules; erythrodermic and poikoilodermous stages which may differ with different stages. The very severe stage of Mycosis fungoides is extracutaneous where any organ may be involved. Only 20 cases of Bulla formation are reported in the literature so far, making it a very rare finding in mycosis fungoides. The majority of reported cases are in adult males. Case presentation: A 45-year-old male, a case of mycosis fungoides IIB, is described in this case report. He presented in an advanced stage of disease with multiple ulcers over the face, bilateral upper limbs, trunk, and back for 6 Months. Conclusion: mycosis fungoides is a very important clinical subtype of cutaneous T-cell lymphoma. Mycosis fungoides IIB represents a particularly aggressive form of mycosis fungoides. The progression of extracutaneous spread in our patient confirms the advanced stage of the disease. The patient was given topical glucocorticoids, which will show improvement. Still, further awareness of the disease among physicians and pathologists is needed. VL - 8 IS - 4 ER -
Information
Email: